Member Sector: Biopharmaceuticals
Methylation Sciences (â€œMSIâ€ or the â€œCompanyâ€) is focused on developing new products based on molecules which have clinical proof of concept but have yet to be exploited in the major pharmaceutical markets. The Company’s first product, STRADAâ„¢, is based on S-adenosyl methionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. The Company has developed superior oral formulations of this molecule with STRADA being the first in clinical development. MSI has a broad intellectual property portfolio and pipeline of candidates.